Biochanin-A has antidiabetic, antihyperlipidemic, antioxidant, and protective effects on diabetic nephropathy via suppression of TGF-β1 and PAR-2 genes expression in kidney tissues of STZ-induced diabetic rats.
Rats
Animals
Diabetic Nephropathies
/ drug therapy
Streptozocin
/ metabolism
Transforming Growth Factor beta1
/ genetics
Antioxidants
/ pharmacology
Hypoglycemic Agents
/ pharmacology
Diabetes Mellitus, Experimental
/ drug therapy
Creatinine
Hypolipidemic Agents
/ metabolism
Receptor, PAR-2
/ metabolism
Kidney
Oxidative Stress
Superoxide Dismutase
/ metabolism
Serum Albumin
/ metabolism
Lipids
PAR-2
TGF-β1
biochanin A
diabetic nephropathy
oxidative stress
Journal
Biotechnology and applied biochemistry
ISSN: 1470-8744
Titre abrégé: Biotechnol Appl Biochem
Pays: United States
ID NLM: 8609465
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
12
05
2021
accepted:
03
10
2021
pubmed:
16
10
2021
medline:
1
11
2022
entrez:
15
10
2021
Statut:
ppublish
Résumé
One of the major complications of diabetes is diabetic nephropathy, and often many patients suffer from diabetic nephropathy. That is why it is important to find the mechanisms that cause nephropathy and its treatment. This study was designed to examine the antidiabetic effects of biochanin A (BCA) and evaluate its effects on oxidative stress markers and the expression of transforming growth factor-β1 (TGF-β1) and protease-activated receptors-2 (PAR-2) genes in the kidney of type 1 diabetic rats. After induction of diabetes using streptozotocin (STZ), 55 mg/kg bw dose, rats were randomly divided into four groups with six rats in each group as follows: normal group: normal control receiving normal saline and a single dose of citrate buffer daily; diabetic control group: diabetic control receiving 0.5% dimethyl sulfoxide daily; diabetic+BCA (10 mg/kg) group: diabetic rats receiving biochanin A at a dose of 10 mg/kg bw daily; diabetic+BCA (15 mg/kg) group: diabetic rats receiving biochanin A at a dose of 15 mg/kg bw daily. TGF-β1 and PAR-2 gene expression was assessed by real-time. Spectrophotometric methods were used to measure biochemical factors: fast blood glucose (FBG), urea, creatinine, albumin, lipids profiles malondialdehyde (MDA), and superoxide dismutase (SOD). The course of treatment in this study was 42 days. The results showed that in the diabetic control group, FBG, serum urea, creatinine, expression of TGF-β1 and PAR-2 genes, and the levels of MDA in kidney tissue significantly increased and SOD activity in kidney tissue and serum albumin significantly decreased compared to the normal group (p < 0.001). The results showed that administration of biochanin A (10 and 15 mg/kg) after 42 days significantly reduced the expression of TGF-β1 and PAR-2 genes and FBG, urea, creatinine in serum compared to the diabetic control group (p < 0.001), also significantly increased serum albumin compared to the diabetic control group (p < 0.001). The level of MDA and SOD activity in the tissues of diabetic rats that used biochanin A (10 and 15 mg/kg) was significantly reduced and increased, respectively, compared to the diabetic control group (p < 0.001). Also, the result showed that in the diabetic control group lipids profiles significantly is disturbed compared to the normal group (p < 0.001), the results also showed that biochanin A (10 and 15 mg/kg) administration could significantly improved the lipids profile compared to the control diabetic group (p < 0.001). It is noteworthy that it was found that the beneficial effects of the biochanin A were dose dependent. In conclusion, administration of biochanin A for 42 days has beneficial effect and improves diabetes and nephropathy in diabetic rats. So probably biochanin A can be used as an adjunct therapy in the treatment of diabetes.
Substances chimiques
Streptozocin
5W494URQ81
Transforming Growth Factor beta1
0
Antioxidants
0
biochanin A
U13J6U390T
Hypoglycemic Agents
0
Creatinine
AYI8EX34EU
Hypolipidemic Agents
0
Receptor, PAR-2
0
Superoxide Dismutase
EC 1.15.1.1
Serum Albumin
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2112-2121Informations de copyright
© 2021 International Union of Biochemistry and Molecular Biology, Inc.
Références
Bagheri F, Amri J, Salehi M, Karami H, Alimoradian A, Latifi SA. Effect of Artemisia absinthium ethanolic extract on oxidative stress markers and the TLR4, S100A4, Bax and Bcl-2 genes expression in the kidney of STZ-induced diabetic rats. Horm Mol Biol Clin Investig. 2020; 41(4):20200028.
Srivastava B, Sen S, Sen K. Free serum sorbitol and its interaction with caffeine: a suggestive approach for plausible remediation of diabetic neuropathy. Biotechnol Appl Biochem. 2020.
Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: prevention and management. J Res Med Sci. 2015;20(11):1112-20.
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64(4):510-33.
Chang AS, Hathaway CK, Smithies O, Kakoki M. Transforming growth factor-β1 and diabetic nephropathy. Am J Physiol Renal Physiol. 2016;15;310(8):F689-96.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106(8):1319-31.
Palygin O, Ilatovskaya DV, Staruschenko A. Protease-activated receptors in kidney disease progression. Am J Physiol Renal Physiol. 2016;311(6):F1140-F4.
Mitsui S, Oe Y, Sekimoto A, Sato E, Hashizume Y, Yamakage Sh, Kumakura S, Sato H, Ito S, Takahashi N. Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease. Am J Physiol Renal Physiol. 2020;318(5):F1067-73.
Waasdorp M, Duitman J, Florquin S, Spek CA, Spek AC. Protease activated receptor 2 in diabetic nephropathy: a double edged sword. Am J Transl Res. 2017;9(10):4512-20.
Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. J Nutr Sci. 2016;5:e47-e.
Umeno A, Horie M, Murotomi K, Nakajima Y, Yoshida Y. Antioxidative and antidiabetic effects of natural polyphenols and isoflavones. Molecules. 2016;21(6):708.
Yu C, Zhang P, Lou L, Wang Y. Perspectives regarding the role of biochanin A in humans. Front Pharmacol. 2019;10:793.
Andugulapati SB, Gourishetti K, Tirunavalli SK, Shaikh TB, Sistla R. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems. Phytomedicine. 2020;78:153298.
Mehrabadi ME, Salemi Z, Bab2272aie S, Panahi M. Effect of biochanin A on retina levels of vascular endothelial growth factor, tumor necrosis factor-alpha and interleukin-1 beta in rats with streptozotocin-induced diabetes. Can J Diabetes. 2018;42(6):639-44.
Oza MJ, Kulkarni YA. Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes. Biomed Pharmacother. 2018;107:1119-27.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
Alaee M, Akbari A, Karami H, Salemi Z, Amri J, Panahi M. Antidiabetic and protective effects of Scrophularia striata ethanolic extract on diabetic nephropathy via suppression of RAGE and S100A8 expression in kidney tissues of streptozotocin-induced diabetic rats. J Basic Clin Physiol Pharmacol. 2020;22;31(2).
Azizi R, Goodarzi MT, Salemi Z. Effect of biochanin A on serum visfatin level of streptozocin-induced diabetic rats. Iran Red Crescent Med J. 2014;5;16(9):e15424.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32:S62-S7.
Morovati A. Effects of biochanin A on resistin, adiponectin and some stress oxidative markers in normal and STZ-induced diabetic rats. Arch Med Lab Sci. 4(2):9-16.
Harini R, Ezhumalai M, Pugalendi KV. Antihyperglycemic effect of biochanin A, a soy isoflavone, on streptozotocin-diabetic rats. Eur J Pharmacol. 2012;15;676(1-3):89-94.
D'Silva LJ, Lin J, Staecker H, Whitney SL, Kluding PM. Impact of diabetic complications on balance and falls: contribution of the vestibular system. Phys Ther. 2016;96(3):400-9.
Zhao J, Wu Y, Rong X, Zheng C, Guo J. Anti-lipolysis induced by insulin in diverse pathophysiologic conditions of adipose tissue. Diabetes Metab Syndr Obes. 2020;13:1575-85.
Kraemer FB, Shen W-J. Hormone-sensitive lipase knockouts. Nutr Metab (Lond) . 2006;3:12-18.
Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015;6(13):1246-58.
Lim AK. Diabetic nephropathy-complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361-81.
Suliman FA, Khodeer DM, Ibrahiem A, Mehanna ET, El-Kherbetawy MK, Mohammad HMF, et al. Renoprotective effect of the isoflavonoid biochanin A against cisplatin induced acute kidney injury in mice: effect on inflammatory burden and p53 apoptosis. Int Immunopharmacol. 2018;61:8-19.
Jayaraman R, Subramani S, Sheik Abdullah SH, Udaiyar M. Antihyperglycemic effect of hesperetin, a citrus flavonoid, extenuates hyperglycemia and exploring the potential role in antioxidant and antihyperlipidemic in streptozotocin-induced diabetic rats. Biomed Pharmacother. 2018;97:98-106.
Anjaneyulu M, Chopra K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol. 2004;31(4):244-8.
Asmat U, Abad K, Ismail K. Diabetes mellitus and oxidative stress-A concise review. Saudi Pharm J. 2016;24(5):547-53.
Guo M, Lu H, Qin J, Qu S, Wang W, Guo Y, et al. Biochanin A provides neuroprotection against cerebral ischemia/reperfusion injury by Nrf2-mediated inhibition of oxidative stress and inflammation signaling pathway in rats. Med Sci Monit. 2019;26;25:8975-83.
Liu X, Wang T, Liu X, Cai L, Qi J, Zhang P, et al. Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Int Immunopharmacol. 2016;38:324-31.
Wang J, He C, Wu WY, Chen F, Wu YY, Li WZ, et al. Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage and oxidative stress in a rat model of Parkinson's disease. Pharmacol Biochem Behav. 2015;138:96-103.
Hajrezaie M, Salehen N, Karimian H, Zahedifard M, Shams K, Al Batran R, et al. Biochanin a gastroprotective effects in ethanol-induced gastric mucosal ulceration in rats. PLoS ONE. 2015;10(3):e0121529-e.
Mitsui S, Oe Y, Sekimoto A, Sato E, Hashizume Y, Yamakage S, et al. Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease. Am J Physiol Renal Physiol. 2020;1;318(5):F1067-73.
Li WZ, Wang XH, Zhang HX, Mao SM, Zhao CZ. Protective effect of the n-butanol Toona sinensis seed extract on diabetic nephropathy rat kidneys. Genet Mol Res. 2016;24;15(1).
Ungefroren H, Gieseler F, Kaufmann R, Settmacher U, Lehnert H, Rauch BH. Signaling crosstalk of TGF-β/ALK5 and PAR2/PAR1: a complex regulatory network controlling fibrosis and cancer. Int J Mol Sci. 2018;19(6):1568.
Kim DH, Kim YR, Bang E, Ha S, Noh SG, Kim BM, et al. Mechanism of lipid accumulation through PAR2 signaling in diabetic male mice. Endocrinol Metab (Seoul). 202;36(1):171-84.